Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from BioNTech SE ( (BNTX) ) is now available.
On January 6, 2026, BioNTech SE reported that CureVac N.V. had completed a previously announced post-offer reorganization related to BioNTech’s exchange offer for all outstanding CureVac shares, resulting in BioNTech becoming the sole owner of CureVac’s business operations and eliminating CureVac’s public shareholder base. In parallel with this transaction, BioNTech amended its Articles of Association—effective December 30, 2025—including updated provisions on share capital and authorization for future capital increases, steps that consolidate control over the acquired CureVac business and provide additional corporate and financing flexibility for BioNTech’s ongoing growth and investment strategy.
The most recent analyst rating on (BNTX) stock is a Buy with a $134.00 price target. To see the full list of analyst forecasts on BioNTech SE stock, see the BNTX Stock Forecast page.
Spark’s Take on BNTX Stock
According to Spark, TipRanks’ AI Analyst, BNTX is a Neutral.
BioNTech’s overall stock score reflects a challenging financial performance with recent losses, offset by a strong balance sheet and strategic advancements in oncology. Technical indicators suggest a neutral trend, while valuation remains unattractive due to negative earnings. The earnings call provided positive guidance, but regulatory delays and financial losses remain concerns.
To see Spark’s full report on BNTX stock, click here.
More about BioNTech SE
BioNTech SE is a German biotechnology company based in Mainz that focuses on the research, development, manufacture and marketing of immunological and RNA-based medicines and diagnostic test methods for the diagnosis, prevention and treatment of cancer, infectious diseases and other serious diseases. The company can also establish, acquire and manage other companies or investments to support its strategic focus in these therapeutic and diagnostic areas.
Average Trading Volume: 1,038,207
Technical Sentiment Signal: Sell
Current Market Cap: $23.29B
Find detailed analytics on BNTX stock on TipRanks’ Stock Analysis page.